According to the Market Statsville Group (MSG), the global intrauterine devices market size is expected to grow from USD 542.8 million in 2022 to USD 1,595.8 million by 2033, at a CAGR of 10.3% from 2023 to 2033.

The effectiveness of IUDs in preventing unwanted pregnancies has been well established, and more and more women are choosing IUDs as their preferred method of contraception. Additionally, IUDs are known to have high user satisfaction, which further increases their demand. Further, there is a growing demand for long-acting reversible contraceptives (LARC), which includes IUDs. Many women prefer LARC methods as they provide long-term protection against unwanted pregnancies, reducing the need for frequent visits to healthcare providers. Additionally, LARC methods are more effective than traditional methods of contraception, such as birth control pills, which need to be taken daily.

Definition of the Global Intrauterine Devices Market

Intrauterine devices (IUDs) are small, T-shaped contraceptive devices are inserted into uterus to prevent pregnancy. They work by preventing egg fertilization or implantation of the fertilized egg in the uterus. IUDs are highly effective at preventing pregnancy, with a failure rate of less than 1%, and they can provide long-term contraception for up to 3-10 years, depending on the type of IUD used. Two types of IUDs are available: hormonal IUDs, which release a small amount of hormones, and copper IUDs, do not contain hormones but are wrapped in copper wire to prevent fertilization. IUDs can only be inserted and removed by a trained healthcare provider.

COVID-19 Impact on the Global Intrauterine Devices Market

The COVID-19 pandemic has significantly impacted the global healthcare industry, including the Intrauterine Devices (IUD) market. One of the major effects of the pandemic has been disruptions in supply chains and access to healthcare services, leading to a shift in the demand for long-acting contraceptive methods such as IUDs. Many women are seeking reliable and long-lasting contraception options due to uncertainties about future access to healthcare services. Additionally, there has been a decline in the number of women seeking routine gynecological care, including contraception services, due to fears of exposure to the virus. This has resulted in a temporary decrease in the demand for IUDs. However, the demand for IUDs is expected to rebound as the pandemic subsides and access to healthcare services improves.

Global Intrauterine Devices Market Dynamics

Drivers: Increase in Government Initiatives and Programs to Promote Family Planning and Control Population Growth

Government initiatives and programs promoting family planning and controlling population growth have significantly driven the Intra Uterine Devices (IUD) market. These programs have been implemented in various countries, particularly in low-income and underprivileged communities, where access to family planning services is limited. Many governments have recognized the importance of promoting family planning to control population growth and improve maternal and child health. As a result, they have implemented programs to increase access to contraceptives, including IUDs. These programs often involve providing education and counseling on family planning and contraception and making contraceptives more accessible and affordable. In addition to promoting family planning, government initiatives have also aimed at improving healthcare infrastructure, particularly in low-income and underprivileged communities, where access to healthcare services is limited. This has increased access to IUDs and other forms of contraception.

Restraints: Lack of Awareness and Misconceptions about IUDs

The lack of awareness and misconceptions about Intra Uterine Devices (IUDs) is one of the main factors that is currently restraining the growth of the IUD market. Many women may not be aware of the benefits of IUDs, or they may have misconceptions about their safety and efficacy. One common misconception about IUDs is that they are only suitable for women with children. This is not true, as IUDs can be safely used by women of all ages, whether they have had children or not. Another misconception is that IUDs can cause infertility. This is also not true, as IUDs do not affect a woman's ability to become pregnant once they are removed. There are also concerns about the safety of IUDs, particularly regarding the risk of infection or perforation of the uterus. While these risks are relatively low, they can contribute to misconceptions about the safety of IUDs.

Opportunities: Growing Technological Advancements

Advancements in technology have played a crucial role in creating new opportunities in the Intra Uterine Devices (IUD) market. One of the most significant developments has been the introduction of hormonal IUDs, which are designed to release a low dose of hormones directly into the uterus. This provides highly effective contraception, with some hormonal IUDs having a failure rate of less than 1%. In addition, hormonal IUDs can also offer other benefits, such as reducing menstrual bleeding and cramps. Non-hormonal copper IUDs have also been developed, providing a highly effective, hormone-free contraception. Copper IUDs work by releasing copper ions into the uterus, which create an environment that is toxic to sperm and prevents fertilization. Advancements in technology have also made IUDs easier and safer to insert and remove. The introduction of smaller and more flexible IUDs has made insertion less painful, and the use of ultrasound guidance has made it easier for healthcare providers to ensure that the IUD is placed correctly. In addition, the use of specialized insertion devices has made the process of inserting and removing IUDs quicker and more efficient.

Scope of the Global Intrauterine Devices Market

The study categorizes the intrauterine devices market based on type and end-user area at the regional and global levels.

By Type Outlook (Sales, USD Million, 2019-2033)

• Nonhormonal: Copper-containing IUD
• Hormonal: Progestogen-releasing IUD

By End-User Outlook (Sales, USD Million, 2019-2033)

• Hospitals
• Clinics
• Community Health Care Centres
• Others

By Region Outlook (Sales, USD Million, 2019-2033)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • Poland
  • Russia
  • The Netherlands
  • Norway
  • Czech Republic
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Thailand
  • Singapore
  • Australia & New Zealand
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Northern Africa
  • Rest of MEA

Hospitals segment accounts for the largest market share by end-use

Based on the end-use, the market is divided into hospitals, clinics, community health care centres, and others. The hospital segment accounted for the largest market share of around 57% in 2022 in the global intrauterine devices market. Hospitals have well-established infrastructure and trained healthcare professionals who are equipped to perform IUD insertions and offer aftercare services. In addition, many hospitals have tie-ups with insurance providers and government healthcare programs, which make IUDs more accessible to patients. Moreover, IUD insertions are often performed in hospitals' outpatient department (OPD), providing a convenient and comfortable environment for patients. This allows for quicker and more efficient insertion procedures and a smoother recovery process. Furthermore, hospitals are also preferred by patients who require IUD removals, as the procedure requires specialized equipment and expertise. Healthcare professionals in hospitals are better equipped to handle any complications that may arise during removal.

Asia Pacific accounted for the largest market share by Region

Based on the regions, the global intrauterine devices market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. Asia Pacific accounted for the largest market share in 2022. The region's large population, increasing awareness about contraception, and rising government initiatives to promote family planning are some of the key factors driving the growth of the IUD market in Asia Pacific. China and India are the largest markets for IUDs in the region, owing to their large populations and high demand for effective and affordable contraceptive methods. In addition, the increasing availability of IUDs through government-funded family planning programs and private healthcare providers is also fostering to the growth of the IUD market in these countries. Furthermore, the rising trend of women delaying childbirth and opting for long-acting reversible contraception methods such as IUDs is also contributing to the growth of the IUD market in Asia Pacific. Many women in the region also seek more comfortable and convenient forms of contraception, which has led to an increasing demand for IUDs.

Competitive Landscape: Global Intrauterine Devices Market

The intrauterine devices market is a significant competitor, and extremely cutthroat in the sector is using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.

Major key players in the global intrauterine devices market are:

• Bayer AG
• CooperSurgical Inc.
• DKT International
• Eurogine
• HLL Lifecare Limited
• Medicines360
• Merck & Co., Inc.
• Mylan N.V.
• Pfizer Inc.
• Prosan International B.V.
• Pregna International Limited
• Abviee Inc.
• Shandong Weigao Group Medical Polymer Company Limited
• Teva Pharmaceutical Industries Ltd.
• Trimedic Supply Network Ltd.

Recent Development

• In December 2022, CooperSurgical, Inc. entered a partnership with Ostro, a platform focused on educating and empowering consumers and healthcare providers, on introducing a fresh consumer engagement solution for the company's hormone-free IUD, Paragard. This partnership will enhance the engagement by educating consumers about CooperSurgical’s Paragard usage.
• In November 2022, The U.S. Food and Drug Administration (FDA) gave its approval to Medicines360's Supplemental New Drug Application (sNDA) to increase the duration of use for Liletta (levonorgestrel-releasing intrauterine system) 52 mg, enabling it to be used for up to eight years for preventing pregnancy.
• In November 2021, DKT WomanCare (WomanCare Global Trading CIC) and Pregna International Ltd. Entered into a partnership to enhance the accessibility of intrauterine contraceptives across the globe. This collaboration involves adding a range of Pregna's top-performing IUDs to DKT WomanCare's worldwide product portfolio, creating a comprehensive reproductive health (RH) offering for governments, bilateral agencies, commercial partners, and social marketing organizations of all types.
• In October 2019, Bayer AG filed a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) to extend the duration of use for its leading intrauterine device (IUD) Mirena (levonorgestrel-releasing intrauterine system) 52 mg. The company has requested an extension of the indication for pregnancy prevention for up to six years, supported by data from a Phase 3 extension trial that examined the safety and efficacy of Mirena.